Guided Therapeutics (GTHP) Equity Average (2012 - 2025)

Guided Therapeutics has disclosed Equity Average across 14 years of filings, most recently posting -$5.8 million for Q4 2025.

• Equity Average for Q4 2025 came in at -$5.8 million, down 19.3% year-over-year; the trailing twelve-month figure through Dec 2025 was -$5.8 million (down 19.3% YoY), and the FY2025 annual result was -$5.4 million, down 25.23% from the prior year.
• Equity Average came in at -$5.8 million for Q4 2025 at Guided Therapeutics, down from -$5.6 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of -$2.8 million in Q4 2022 to a low of -$9.4 million in Q1 2021.
• The 5-year median for Equity Average is -$4.9 million (2024), against an average of -$5.1 million.
• Across the five-year window, Equity Average soared 58.05% in 2022 and sank 40.66% in 2024, its largest moves.
• Guided Therapeutics' Equity Average stood at -$6.6 million in 2021, then jumped by 58.05% to -$2.8 million in 2022, then sank by 34.73% to -$3.7 million in 2023, then plunged by 31.53% to -$4.9 million in 2024, then decreased by 19.3% to -$5.8 million in 2025.
• The last three Equity Average figures came in at -$5.8 million (Q4 2025), -$5.6 million (Q3 2025), and -$5.2 million (Q2 2025), per Business Quant data.